Will Dextera Surgical Inc (NASDAQ:DXTR) Ever Fly High Again?

Dextera Surgical Inc (NASDAQ:DXTR)

Dextera Surgical Inc (NASDAQ:DXTR)

In 2011, shares of Dextera Surgical Inc (NASDAQ:DXTR) were trading above $50. Today the stock is trading below $0.20 as investors await the company’s Q1 2018 earnings announcement. The announcement will take place on Thursday, November 9, 2017, after the markets close. Analysts are expecting a loss of (-$0.06) per share.


DXTR stock last traded above the $1 level in May of 2017. This is not only a psychologically important level, but it also has a regulatory aspect to it. Section 5550(a)(2) of the Nasdaq’s Equity Rules guide states: “(a) Continued Listing Requirements for Primary Equity Securities: (2) Minimum bid price of at least $1 per share.” Frequently companies that in violation of the “$1 Bid” NASDAQ rule complete a reverse stock split to maintain compliance. So far, there has been no news on such an eventuality from Dextera.

Dextera Surgical Inc (NASDAQ:DXTR) designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted, or robotic-assisted surgical procedures annually. Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System.

DXTR Stock

Despite the multi-year downtrend and the recent EPS losses, two analysts rate DXTR stock as a “Strong Buy” while one rates DXTR stock as a “Hold”. Their consensus, one-year price target is $0.70. Earnings were projected to be -29% for 2017 but are projected at +16% for next year.

DXTR shareholders have had a rough 2017 so far. Year-to-date, DXTR shares are down over 80% and for the year shares are down over 88%.

EPS for DXTR stock has been negative since 2012 but improved each year until 2016, then a loss of (-$2.33) was posted for 2017. Sales have been rather consistent. In 2013 sales were posted at $3.5 million and that number did not substantially change over the next four years.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DXTR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *